newsfilter
← Latest News
GlobeNewswire·

Graybug Vision Reports Full-Data Analysis from 12-Month Treatment Phase of ALTISSIMO Phase 2b Trial in Wet AMD

GB-102 1mg has shown competitive durability and anatomical control versus aflibercept Trend in mean BCVA of GB-102 1mg compared to aflibercept driven primarily by a subgroup of patients Developing enhanced formulations and seeking partner funding for